OVERVIEW

Nontuberculous Mycobacteria (NTM) Lung Disease: Advancing Detection, Optimizing Therapy, and Improving Patient Quality of Life is organized by Medical Learning Institute Inc (MLI).

Release Date: Jun 19, 2026
Expiration Date: Jun 18, 2027

Description:
NTM-LD is a rare but serious condition, most commonly caused by Mycobacterium avium complex (MAC), and disproportionately affects patients with underlying lung diseases such as bronchiectasis, chronic obstructive pulmonary disease (COPD), and asthma—leading to delayed diagnosis, progressive lung damage, and diminished quality of life. 

Unlike traditional lectures, this Dialogues program brings attendees into the conversation. Through real-time audience interaction, multidisciplinary expert insights, and real-world patient cases, you’ll explore the complexities of NTM-LD alongside leading specialists in an engaging, studio-quality format. This expert-led activity will include discussion and audience-driven dialogue as participants will examine current and emerging treatment strategies, including approaches for recurrent infection, and explore how evidence-based therapeutic decision-making can optimize clinical outcomes and improve patient quality of life. 

Learning Objectives:
After completing this activity, the participant should be better able to:

  • Describe the epidemiology and clinical burden of NTM-LD
  • Identify patients at risk of NTM-LD using standard diagnostic tools such as radiological and microbiological analysis
  • Apply current and emerging treatment options for NTM-LD, including those for recurrent infections based on the latest clinical data to enhance patient QoL
Credits

Credits:
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education:
Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Continuing Certification Statement:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Thoracic Surgery’s Maintenance of Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABTS credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

For Physicians requesting ABIM MOC or ABTS CC credit, the post-test and evaluation are required in their entirety as well as your ABIM or ABTS ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC/CC credit.

Notice to Diplomates: MLI will report any claimed MOC/Lifelong Learning points to the appropriate Board within 4 weeks of completing the activity. Please ensure that you have provided your Board ID number and MMDD of birth. 

PA:
Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until June 18, 2027. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development:
Successful completion of this nursing continuing professional development activity will be awarded 1.5 contact hours and 0.5 contact hour in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement:
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • 1.5 AMA PRA Category 1 Credits™
  • 1.5 MOC
  • 1.5 IPCE
  • 1.5 Contact Hours
  • 1.5 AAPA
  • TARGET AUDIENCE

    Primary Care PhysicianCliniciansInfectious Diseases PhysicianImmunologists

    SPECIALITIES

    Allergy and ImmunologyInfectious DiseasePrimary CarePulmonologists

    RELATED ONLINE COURSES